Adicet Bio announces positive safety and efficacy data from prula-cel study in lupus patients
ACET•Adicet Bio said prula-cel was well tolerated, with 54% of patients achieving DORIS remission and 50% achieving complete renal response at 12 months; the company plans to start pivotal lupus nephritis trial activities in Q4 2026.
1. Study results
Adicet Bio reported positive safety and efficacy data for prula-cel in patients with systemic lupus erythematosus, with or without lupus nephritis. The treatment was well tolerated, with no cytokine release syndrome above grade 2 and no IEC-HS or ICANS; all patients discontinued immunosuppressants.
2. Next steps
At 12 months, 54% achieved DORIS remission and 50% achieved complete renal response. Adicet plans to initiate start-up activities for a pivotal lupus nephritis trial in Q4 2026 and anticipates a clinical data update in lupus nephritis and systemic lupus erythematosus in mid-2027.
